Condition: Hepatocellular Carcinoma · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
This description comes directly from the study's public registry record.
Peter Galle, Prof. Dr. · 0049 6131 177275 · peter.galle@unimedizin-mainz.de
Johanna Riedel, Dr. · 0049 697 601 4635 · riedel.johanna@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| LKH - Univ. Klinikum Graz | Graz, Austria | Recruiting |
| Medzinische Universität Innsbruck | Innsbruck, Austria | Recruiting |
| Klinikum Klagenfurt am Wörthersee | Klagenfurt, Austria | Recruiting |
| Ordensklinikum Linz | Linz, Austria | Recruiting |
| Universitätsklinikum St. Pölten | Sankt Pölten, Austria | Recruiting |
| Medizinische Universität Wien | Vienna, Austria | Recruiting |
| Institut Sainte-Catherine | Avignon, France | Recruiting |
| Hôpital Jean-Verdier Avicenne | Bobigny, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| CHU Clermont-Ferrand CHU Estaing | Clermont-Ferrand, France | Recruiting |
| Beaujon Hospital | Clichy, France | Recruiting |
| CHU Grenoble | Grenoble, France | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04803994